JAKPOT T1D
- Study HIC#:2000035456
- Last Updated:09/04/2024
TrialNet is testing two different Janus kinase (JAK) inhibitors to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
The two JAK inhibitors being tested in this study are abrocitinib and ritlecitinib. To understand which treatment works best, participants will be randomly assigned to one of three groups: one group will get abrocitinib, one will get ritlecitinib, and one will get a matching placebo (looks like the study treatment but has no active ingredients).
Contact Us
For more information about this study, including how to volunteer, contact:
Marcia DeSousa at The Yale Pediatric Diabetes Program
- Phone Number: 1-203-737-4805
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
This study is enrolling people who are:
• Age 12-35
• Newly diagnosed with T1D (in past 3 months)
AND have:
• 1 or more diabetes-related autoantibodies
• Hemoglobin A1C below 10%
• C-peptide detectable during a mixed-meal tolerance test (MMTT)
